<https://rdf.molmedb.upol.cz/reference/ref876> <http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM01053>;
	<http://purl.org/ontology/bibo/doi> "10.1124/jpet.105.091223"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/transporter/target2>,
		<https://identifiers.org/molmedb/MM467582>,
		<https://identifiers.org/molmedb/MM17052>,
		<https://identifiers.org/molmedb/MM16896>,
		<https://identifiers.org/molmedb/MM467582.1>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource>;
	<http://purl.org/ontology/bibo/pmid> "16141367"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/bibliographicCitation> "Bourdet DL, Pritchard JB, Thakker DR.: Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther, Volume 315 (3), 2005"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM00079> .
<https://rdf.molmedb.upol.cz/transporter/tra32273> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref876> .
<https://rdf.molmedb.upol.cz/transporter/tra32253> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref876> .
<https://rdf.molmedb.upol.cz/transporter/tra32342> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref876> .
<https://rdf.molmedb.upol.cz/transporter/tra32083> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref876> .
<https://rdf.molmedb.upol.cz/transporter/tra32393> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref876> .